Hydroxamate-based, cereblon-based and PROTACs designed onto Y-shaped HDAC6s [306,307,308] have been demonstrated to potently degrade HDAC6 and to be efficient in restraining HDAC6-dependent inflammatory events and impair cancer cells’ proliferation [309,310,311]. The gene discussed is HDAC6; the disease is cancer.